BIOSYNEX SA announced the extension of its partnership with the Singaporean company Credo Diagnostics Biomedical Pte Ltd. The collaboration between the two companies had started at the beginning of the Covid-19 health crisis in March 2020, which eventually led to an agreement to distribute VitaPCRTM systems in France, Belgium, Switzerland and Luxembourg. Founded in 2011, Credo Diagnostics launched the VitaPCRTM in 2019, a revolutionary molecular biology platform capable of detecting infectious pathogens by Polymerase Chain Reaction methodology in only 20 minutes. With its ease of use, VitaPCRTM contributes significantly to the decentralization of tests from centralized labs to private medical laboratories, general hospitals or even directly by nursing staff in clinical departments.

In more than two years of partnership, BIOSYNEX has successfully implemented the VitaPCRTM solution in more than 300 sites in France, including private clinical laboratories, hospitals, and remote sites. BIOSYNEX and Credo Diagnostics have recently strengthened their collaboration by signing an exclusivity agreement for an extended territory including the United Kingdom. Thanks to the acquisition of BHR in May 2022, BIOSYNEX now has a direct sales force in the United Kingdom and anticipates a significant deployment of the VitaPCRTM systems in this country which is at the forefront of Point-of-Care diagnostic solutions.

In addition, Credo Diagnostics will be releasing a next generation rapid PCR platform, VitaSIRO soloTM based on microfluidic technology that simplifies the entire procedure. The multiplexing capability of the new platform enables the simultaneous viral detection of influenza, SARS-CoV-2 and Respiratory Syncytial Virus that cause bronchiolitis. This new respiratory assay was developed with the intention of meeting the diagnostic demand linked to winter respiratory epidemics due to multiple viruses and will strengthen the diagnostics portfolio of Credo Diagnostics.

Furthermore, new applications are being developed on this platform and will enable BIOSYNEX to expand its solution offer to existing customers as well as future prospects.